Zevra Therapeutics resubmits Orphazyme asset to FDA

Zevra Therapeutics has been working to convince the FDA of arimoclomol’s benefits for years. Now the biotech company will see if it has been sucessful. 
Photo: Andrew Kelly/Reuters/Ritzau Scanpix
Photo: Andrew Kelly/Reuters/Ritzau Scanpix

Zevra Therapeutics believes that it has now completed Orphazyme’s work. Therefore, after several postponements, the American biotech company has submitted the final re-application for marketing authorization for Orphazyme’s former crown jewel, arimoclomol. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Photo: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading